There are currently 1874 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
NCT02744677
Recruiting
This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention.
Gender:
ALL
Ages:
All
Trial Updated:
12/16/2024
Locations: Penn Presbyterian Medical Center, University of Pennsylvania/ Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Register for Updates
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
Recruiting
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
Conditions: Cervical Cancer
Register for Updates
VIBRANT: VIB4920 for Active Lupus Nephritis
NCT05201469
Recruiting
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology, Philadelphia, Pennsylvania
Conditions: Lupus Nephritis
Register for Updates
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
NCT05364502
Recruiting
To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Arterial Bleeding in Solid Organs and Peripheral Arteries
Register for Updates
Endovascular Engineering ENGULF Study
NCT05597891
Recruiting
Evaluation of initial safety and clinical feasibility of the Hēlo PE Thrombectomy System for thrombectomy in acute submassive pulmonary embolism (PE).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
12/13/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pulmonary Embolism
Register for Updates
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
NCT03511118
Recruiting
Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying. We are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the amount of drug that is transferred to breastmilk and estimate how much of drug that is consumed by bre... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/12/2024
Locations: Hospital of the University of Pennsylvania Department of Maternal Fetal Medicine, Philadelphia, Pennsylvania
Conditions: Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Register for Updates
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
NCT04496687
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Spontaneous Coronary Artery Dissection
Register for Updates
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814
Recruiting
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
Gender:
MALE
Ages:
Between 4 years and 14 years
Trial Updated:
12/12/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML
NCT06679582
Recruiting
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children must have a leukemia which did not respond or recurred after prior treatment. Luveltamab tazevibulin is an antibody-drug conjugate, which brings tazevibulin, an anticancer drug, to a molecule called FOLR1, present on the surface of CBFA2T3::GLIS2 AML... Read More
Gender:
ALL
Ages:
Between 1 day and 12 years
Trial Updated:
12/12/2024
Locations: Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania
Conditions: Acute Myeloid Leukemia (AML)
Register for Updates
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rat... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/11/2024
Locations: University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
NCT06006546
Recruiting
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/11/2024
Locations: Penn Prevention CRS, Philadelphia, Pennsylvania
Conditions: Chronic HIV Infection
Register for Updates